Page last updated: 2024-09-04

canertinib and Carcinoma, Epidermoid

canertinib has been researched along with Carcinoma, Epidermoid in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J1
Ako, E; Hirakawa, K; Hori, T; Kubo, N; Ohira, M; Sawada, T; Yamashita, Y; Yamazaki, M1
de Bock, C; Denny, WA; Ferguson, LR; Gieseg, MA1

Reviews

1 review(s) available for canertinib and Carcinoma, Epidermoid

ArticleYear
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
    Bulletin du cancer, 2003, Volume: 90 Spec No

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines

2003

Other Studies

2 other study(ies) available for canertinib and Carcinoma, Epidermoid

ArticleYear
The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
    Oncology reports, 2007, Volume: 17, Issue:4

    Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Xenograft Model Antitumor Assays

2007
Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033.
    Anti-cancer drugs, 2001, Volume: 12, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Division; Cells, Cultured; Cisplatin; DNA Adducts; DNA Repair; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Fibroblasts; Humans; Luciferases; Mice; Morpholines; Tumor Cells, Cultured

2001